Our breeding strategy segregates breeders with loxP-flanked alleles from those transgenic for Cre; specifically, we intercrossed R26R YFP/YFP with mice heterozygous for the transgene encoding UBC-CreT2 to generate R26R YFP/+ UBC-CreT2 + offspring (Supplementary Methods).
After initiating the administration of feed containing ivermectin (12 p.p.m.), we unexpectedly found that approximately 60% of the R26R YFP UBC-CreT2 + offspring expressed YFP in peripheral blood cells (Fig. 1a) . Deletion was not confined to the Rosa26 locus; many additional loxP-flanked loci present in our colony underwent recombination in UBC-CreT2 + mice treated with ivermectin (data not shown). Breeding cages continued to generate offspring with YFP + cells more than 15 weeks after the cessation of ivermectin treatment. Notably, adult R26R YFP/+ UBC-CreT2 + mice weaned before the initiation of treatment responded very differently and remained YFP -despite direct ingestion of ivermectin-containing feed (data not shown). Neither the R26R YFP knock-in allele nor the transgene encoding UBC-CreT2 alone was sufficient for YFP expression induced by ivermectin (data not shown).
To determine if CreT2-mediated deletion induced by ivermectin occurred in all tissues or only a subset of tissues, we evaluated YFP expression in histology sections of thymuses, spleens and kidneys from R26R YFP/+ UBC-CreT2 + , R26R YFP/+ UBC-CreT2 -and tamoxifentreated mice. Oral treatment with tamoxifen resulted in YFP expression regardless of cell or tissue type (data not shown). In contrast, ivermectin treatment resulted in limited distribution of YFP expression, with YFP detected in spleen and thymus but not kidney tissue in ivermectin-treated
To the Editor:
Ivermectin is a broad-spectrum antihelmintic drug used to treat pinworms and fur mites in laboratory mouse colonies. Here we report activation of a tamoxifen-regulated Cre recombinase fusion protein as an unintended but immunologically relevant side effect of oral treatment with ivermectin.
Ectoparasites and their treatment represent a growing dilemma in laboratory mouse colonies 1, 2 . Topical or oral ivermectin is an effective treatment for fur mites and pinworms because ivermectin selectively binds to the glutamate-gated chloride ion channels in muscle and nerve cells, leading to hyperpolarization of the cells, followed by paralysis and death of the parasite 3 . Ivermectin is generally considered to be safe for rodent colonies but may alter immune responses 4 and has neurotoxicity in susceptible strains 5 .
During a facility-wide treatment for mite infestation, we noted unexpected deletion of the loxP-flanked 'stop' cassette of a reporter for the expression of Cre recombinase from the ubiquitously expressed Rosa26 promoter with knock-in of sequence encoding yellow fluorescent protein (R26R YFP ) 6 in two independent colonies of mice with transgenic tamoxifen-regulated expression of Cre (UBC-CreT2) 7 . Normally the CreT2 fusion protein, transcriptionally regulated here by the ubiquitin promoter, is inactive unless bound specifically to 4-hydroxytamoxifen or estrogen antagonist ICI 182780 (ref. 8) . In over 5 years of experience with the UBCCreT2 and R26R YFP strains, we have not noted CreT2-mediated deletion in hematopoietic lineages without tamoxifen exposure 9 (data not shown).
Oral ivermectin as an unexpected initiator of CreT2-mediated deletion in T cells mice (data not shown), which suggested potential hematopoietic specificity. Systematic examination of splenic populations by flow cytometry confirmed that YFP was expressed by up to 80% of CD4 + T cells and CD8 + T cells but <1% of B lymphocytes (Fig. 1b) . Because deletion was somewhat restricted to T cells, we further evaluated thymocytes from ivermectin-treated mice to determine when deletion occurred during T cell development. T cell development seemed grossly normal in all mice (data not shown). YFP was first detectable between the CD4 -CD8 -CD25 + CD44 -stage (double-negative stage 3) and CD4 + CD8 + stage (double-positive stage) of T cell development (Fig.  1c) .
We propose the following potential mechanism to explain the findings presented above. As the deletion occurred in offspring before weaning and not in genotypically identical ivermectin-treated adult mice, we believe that metabolites may be transmitted transplacentally and/ or via lactation. Secretion of ivermectin correlates with the fat content of milk 10 . It is possible that fat stores in the mother act as a reservoir, which would explain how deletion was able to occur long after ivermectin treatment had been stopped. Regardless of the underlying mechanism, the persistent finding of CreT2-mediated deletion in offspring born from breeders given temporally distant treatment resulted in the time-consuming need to generate new breeder pairs.
We report these findings to inform the community of this unintended effect of ivermectin treatment. The consequences of ivermectin-induced deletion, although they were confined to offspring rather than previously weaned mice, rendered both breeders and offspring unusable for future experiments. Breeding cages of parents free of ivermectin from birth subsequently produced offspring without evidence of tamoxifenindependent deletion. Thus, a minimum of 22 weeks is needed to generate mature (6-to 8-week-old) mice after ivermectin treatment has ended. Because of the long-term effects of oral ivermectin on mice via temporal tamoxifen-induced deletion, caution should be taken before treatment is begun. 
